On July 30, the State Food and Drug Administration announced that, entrusted by Goli Pharmaceutical Co., LTD., Lavidavir hydrochloride, a class 1 new hepatitis C drug, was successfully approved for the phase I clinical study undertaken by Duzheng Biology (Hunan Maternal and Child Health Hospital and The Second People's Hospital of Nanning were in charge of clinical work, leading medicine was in charge of recruitment and SMO service, farmed data execution data management and statistical analysis).
Ravidavir hydrochloride is an NS5A inhibitor that inhibits viral RNA replication. NS5A is a multifunctional protein that is an essential component of the HCV replication complex. The introduction of this product will provide more therapeutic options for non-cirrhotic adult patients with newly treatable genotype 1B chronic hepatitis C virus infection. For the treatment of treatable genotype 1B chronic hepatitis C virus infection in noncirrhotic adults. The drug was originally developed by Presidio (PPI-668) and licensed to Goeli (ASC-16) in 2014 for the treatment of hepatitis C.
Duzheng Biotech is committed to providing phase ⅰ, ⅱ, ⅲ and ⅳ clinical trial services to drug r&d institutions worldwide, including: medical affairs, clinical research, data management and statistical analysis, registration affairs, policy consulting, etc. With "scientific, professional, standardized and efficient" services to help bid to promote the product listing process.